TABLE 2.

Therapeutic effect of LPC in combination with colistin, tigecycline, or imipenem in murine peritoneal sepsis model with A. baumannii ATCC 17978

Treatmenta	n	Log10 CFU/g (mean ± SEM)		% sterile blood cultures	Mouse survival (%)b
		Spleen	Lungs
CTL	13	9.72 ± 0.09	8.74 ± 0.18	0	0**
LPC	15	5.81 ± 0.72c	6.37 ± 0.62c	60c	40c**
CST	15	0c,d	0c,d	0c,d	100c,d**
LPC+CST	15	0c,d	0c,d	0c,d	100c,d**
TGC	15	3.00 ± 0.57c,d	4.60 ± 0.60c,d	93.33c,d	93.33c,d**
LPC+TGC	15	0.35 ± 0.35c,d,e	2.66 ± 0.58c,d,e	0c,d	100c,d**
IMP	15	0c,d	0c,d	0c,d	100d*
LPC+IMP	15	0c,d	0c,d	0c,d	100e*

^aCTL, control (no treatment); LPC, lysophosphatidylcholine; CST, colistin; TGC, tigecycline; IMP, imipenem.

^b*, mouse mortality was recorded over 24 h; **, mouse mortality was recorded over 72 h.

^cP < 0.05 compared to the controls.

^dP < 0.05 compared to the LPC group.

^eP < 0.05 compared to the TGC group.